Correction to “Outcomes of patients with initially unresectable pancreatic cancer who underwent conversion surgery after FOLFIRINOX or gemcitabine plus nab-paclitaxel chemotherapy: A multicenter retrospective cohort study (PC-CURE-1)”
{"title":"Correction to “Outcomes of patients with initially unresectable pancreatic cancer who underwent conversion surgery after FOLFIRINOX or gemcitabine plus nab-paclitaxel chemotherapy: A multicenter retrospective cohort study (PC-CURE-1)”","authors":"","doi":"10.1002/jhbp.12096","DOIUrl":null,"url":null,"abstract":"<p>Naohiro O, Manabu K, Makoto U, Xianjun Y, Yosuke I, Shinichiro T, et al. Outcomes of patients with initially unresectable pancreatic cancer who underwent conversion surgery after FOLFIRINOX or gemcitabine plus nab-paclitaxel chemotherapy: A multicenter retrospective cohort study (PC-CURE-1). <i>J Hepatobiliary Pancreat Sci</i>. 2024;31:816-829. https://doi.org/10.1002/jhbp.12066</p><p>In section 3.3 Adjuvant therapy and mode of relapse, the sentence “Among these patients, 51 (26.3%) experienced relapse. The most common sites were the liver (18.0%), local (17.5%), lungs (17.0%), and peritoneum (11.3%).” should read as below,</p><p>“Among these patients, 143 (73.7%) experienced relapse. The most common sites were the liver (19.1%), local (18.0%), lungs (18.0%), and peritoneum (12.9%).”</p><p>We apologize for this error.</p>","PeriodicalId":16056,"journal":{"name":"Journal of Hepato‐Biliary‐Pancreatic Sciences","volume":"32 2","pages":"177"},"PeriodicalIF":3.2000,"publicationDate":"2025-01-08","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://onlinelibrary.wiley.com/doi/epdf/10.1002/jhbp.12096","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Journal of Hepato‐Biliary‐Pancreatic Sciences","FirstCategoryId":"3","ListUrlMain":"https://onlinelibrary.wiley.com/doi/10.1002/jhbp.12096","RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q2","JCRName":"GASTROENTEROLOGY & HEPATOLOGY","Score":null,"Total":0}
引用次数: 0
Abstract
Naohiro O, Manabu K, Makoto U, Xianjun Y, Yosuke I, Shinichiro T, et al. Outcomes of patients with initially unresectable pancreatic cancer who underwent conversion surgery after FOLFIRINOX or gemcitabine plus nab-paclitaxel chemotherapy: A multicenter retrospective cohort study (PC-CURE-1). J Hepatobiliary Pancreat Sci. 2024;31:816-829. https://doi.org/10.1002/jhbp.12066
In section 3.3 Adjuvant therapy and mode of relapse, the sentence “Among these patients, 51 (26.3%) experienced relapse. The most common sites were the liver (18.0%), local (17.5%), lungs (17.0%), and peritoneum (11.3%).” should read as below,
“Among these patients, 143 (73.7%) experienced relapse. The most common sites were the liver (19.1%), local (18.0%), lungs (18.0%), and peritoneum (12.9%).”
期刊介绍：
The Journal of Hepato-Biliary-Pancreatic Sciences (JHBPS) is the leading peer-reviewed journal in the field of hepato-biliary-pancreatic sciences. JHBPS publishes articles dealing with clinical research as well as translational research on all aspects of this field. Coverage includes Original Article, Review Article, Images of Interest, Rapid Communication and an announcement section. Letters to the Editor and comments on the journal’s policies or content are also included. JHBPS welcomes submissions from surgeons, physicians, endoscopists, radiologists, oncologists, and pathologists.
求助内容：
应助结果提醒方式：
京公网安备 11010802042870号
